SEC Form 4 · accession 0000943819-26-000035
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Farrell
Officer — Chairman and CEO · Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 9, 2026 · 2:26 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Jun 8, 2026 | M | 4,991 | $146.34 | A | 471,214 | D | |
| ResMed Common StockF2,F3 | Jun 8, 2026 | S | 4,991 | $193.962 | D | 466,256 | D | |
| ResMed Common Stock | holding | — | — | — | 2,090 | I | Lisette and Michael Farrell Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock Options | $146.34 | Jun 8, 2026 | M | 4,991 | D | Nov 11, 2020 | Nov 21, 2026 | ResMed Common Stock | 4,991 | 24,957 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- F2This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price.
- F3Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.